Paul Moore
Chief Scientific Officer Zymeworks
Paul Moore, PhD, is Chief Scientific Officer at Zymeworks, where he leads research and early development across the company’s portfolio of multispecific antibody and biotherapeutic programs. He brings more than 25 years of experience in biologics drug discovery and development, with a track record of contributing to multiple FDA-approved and clinical-stage therapies across oncology and autoimmune diseases. Prior to joining Zymeworks, Paul served as Vice President of Cell Biology and Immunology at MacroGenics, where he led large research teams advancing antibody-based therapeutics, including bispecifics and antibody–drug conjugates. Earlier in his career, he held senior roles at Celera and Human Genome Sciences, contributing to genomic target discovery programs and the development of biologics for complex diseases.
Seminars
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
- What is the path to success for novel payloads, including how to navigate early assessment of payload platforms?
- What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success?
- Discussing the panellists’ approach to business development. What would a win/ win business deal look like that focuses on payloads?
